Synlogic falls as it axes lead program

Synlogic dropped $1.34 (28%) to $3.49 after announcing the discontinuation of its lead program, SYNB1020 for hyperammonemia, based on interim Phase Ib/IIa data showing futility.

CEO Aoife Brennan told BioCentury the trial's top-line data indicated the SYNB1020 program was futile and unlikely to benefit patients...